LEXINGTON, Mass.--(BUSINESS WIRE)--Elpis Biopharmaceuticals, a biopharmaceutical company developing next generation multifunctional immunotherapies to transform cancer treatment, today announced the ...
LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today ...
Research highlights potential of EPC-002 in the treatment of solid tumors and EPC-003 for the treatment of glioblastoma The first poster, LB363, titled, "Multi-mechanism human B7H3 CAR-T effectively ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, today presented two ...
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and ...
LEXINGTON, Mass. and SINGAPORE, June 4, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results